Skip to main content

Table 2 Means and standard deviations of groups at baseline, 6 weeks and 3 months follow-up

From: A novel brief treatment for methamphetamine use disorders in South Africa: a randomised feasibility trial

Variable Control (mean [sd]) IDMI (mean [sd])
Substance use (days in 2 weeks)
 Baseline 8.57 (4.29) 9.73 (3.95)
 6 week follow-up 6.43 (4.62) 4.83 (4.86)
 3 month follow-up 6. 90 (4.12) 4.80 (4.97)
Cravings (PENN craving)
 Baseline 22.50 (6.85) 20.37 (7.50)
 6 week follow-up 17.43 (8.35) 15.97 (7.61)
 3 month follow-up 13.13 (10.09) 14.83 (8.35)
Depression (HAM-D)
 Baseline 12.50 (5.25) 12.90 (6.22)
 6 week follow-up 11.23 (5.83) 10.20 (6.50)
 3 month follow-up 8.40 (5.37) 8.53 (6.69)
Anxiety (HAM-A)
 Baseline 20.27 (10.19) 18.70 (10.02)
 6 week follow-up 17.73 (10.08) 13.87 (9.27)
 3 month follow-up 14.63 (9.44) 8.79 (8.00)
Clinical Global Impressions Scale (CGI)
  Baseline 5.13 (0.97) 5.27 (0.91)
 6 week follow-up 4.57 (1.72) 4.03 (1.65)
  3 month follow-up 4.00 (1.89) 3.60 (1.81)
Sheehan disability (family)
 Baseline 8.40 (2.43) 7.77 (2.91)
 6 week follow-up 6.47 (4.02) 5.53 (3.69)
 3 month follow-up 4.50 (3.97) 4.43 (3.31)
Sheehan disability (work)
 Baseline 6.07 (3.85) 7.30 (2.49)
 6 week follow-up 4.70 (4.27) 5.50 (3.42)
 3 month follow-up 4.00 (3.80) 4.50 (3.75)
Sheehan disability (social life)
 Baseline 7.78 (2.27) 7.50 (2.86)
 6 week follow-up 5.53 (4.08) 4.70 (3.96)
 3 month follow-up 3.63 (3.93) 4.27 (3.63)